call Toll Free (US/Canada): +1 866 658 6826 | call+1 425 320 4776 | call (UK): +44 1865 60 0662 | call (Ind): +91 9096278110 | email info(@)blueweaveconsulting.com
Home | About Us | Career | Services | Blog | Contact Us
Blueweave
Antibody Drug Conjugates Adc Market
Inquire Before Buying Request for Sample

Antibody Drug Conjugates Adc Market

Home Healthcare And Pharmaceutical Antibody Drug Conjugates Adc Market

Antibody Drug Conjugates (ADC) Market- Global Industry Size, Share, Trend, Growth, Opportunity and Forecast, 2017-2027, Segmented By Type (Cleavable Linker and Non-cleavable Linker), By Application (Blood Cancer (Leukemia, Multiple Myeloma, Lymphoma, Breast Cancer, Urothelial Cancer & Bladder Cancer and Others), By End Users (Research Institutes, Biotechnology Companies, Hospitals, and Clinics), By Region (North America, Europe, The Asia-Pacific (APAC), Latin America (LATAM), The Middle-East & Africa (MEA)),

  • Published Date: February 2022
  • Report ID: BWC22032
  • Available Format: PDF
  • Page: 210

Report Overview

The growing advancement in linker technology coupled with extensive research & development in the medical field has driven the growth of the global ADC market.

Global Antibody Drug Conjugates (ADC) Market - Industry Trends & Forecast Report 2027

The global Antibody Drug Conjugates (ADC) market reached a market valuation of USD 4,053.7 million in 2021 and the market is further anticipated to reach USD 14,484.2 million by 2027, exhibiting a robust CAGR of 25.2% during the forecast period, i.e., 2022-2027. Increasing advancements in linker technology, coupled with extensive research & development in the medical field, has driven the growth of the global ADC market. Another major factor for the growth of the ADC is the growing incidence of cancer cases across the globe. It has been found that antibody-drug conjugates may be therapeutic and effective for eliminating cancer tumors by delivering chemotherapy through a linker attached to the monoclonal antibody to specifically target cancer cells. The WHO estimates that by 2040, cancer cases will reach 30.2 million, which will increase the need for ADC drugs. In addition to this, the increasing regulatory approvals for the drugs have further accelerated the market's growth.

Global ADC Market

Antibody Drug Conjugate – A Brief Overview

Antibody-drug conjugates (ADC) are targeted medicines or drugs that deliver chemotherapy agents to kill cancer cells. Antibody-drug conjugates deliver chemotherapy using a linker attached to a monoclonal antibody directed against a specific target on the surface of cancerous cells.

An ADC releases a cytotoxic chemical into the cancer cell after attaching to the target and killing it from roots. In comparison to chemotherapy, the ADC is widely prescribed by doctors since it does not damage healthy cells. The components that make ADC are tumor antigen-specific monoclonal antibodies, stable chemical linkers, and potent cytotoxic molecules (also called payloads).

Global Antibody Drug Conjugates (ADC) Market Trends

Growth Drivers

Increasing Prevalence's of Cancer Cases

Antibody-drug conjugates (ADC) happen to be targeted medicines that create chemotherapy agents for fighting cancer cells. As As a result, they play a pivotal role in treating patients with cancer of all types, including but not limited to blood cancer, breast cancer, and others. The rising number of cancer cases across the world has become a contributing factor to the growth in demand for ADC drugs. According to the WHO, the number of cancer cases recorded for the year 2020 were around 19.3 million. According to the WHO estimates, the figure is anticipated to grow and reach 30.2 million by 2040, suggesting a sharp increase in cancer cases per year. Breast cancer and lung cancer happen to be the most significant contributors to cancer cases worldwide. Thus, the rising cancer across developing and developed nations are anticipated to drive the global ADC market during the forecast period positively.

Opportunity

Rising Collaborations across BioPharmaceutical Companies

With the increasing number of collaborations between various pharmaceutical companies to develop more effective and robust ADC drugs, numerous growth opportunities are being created across the market. A number of pharmaceutical and biomedical companies have announced their intent to integrate their expertise and technology along with their research experience to develop targeted antigen ADC drugs for commercialization. For Instance, in September 2021, a co-development agreement for antibody immune agonist conjugate (AIAC) was developed, named GQ1007. It was inked by BrighGene Biomedical (Suzhou) Co. Ltd. and GeneQuantum Healthcare Co., Ltd. Also in July 2020, AstraZeneca plc announced its collaboration with Daiichi Sankyo for DS-1062, a novel ADC candidate in its Phase 1 trial studies for non-small cell lung cancer (NSCLC) and triple-negative breast cancer. Such collaborative initiatives across pharmaceutical companies are paving the way for cost-saving measures, thereby reducing the overall price of the drug and making it more widely available.

Impact of COVID-19 on the Global ADC Market

The COVID-19 pandemic has contributed to the decline in treatment for various diseases such as cancer, heart disease, and more. Of these treatments, cancer has been the most adversely affected because it is an alarming disease, yet patients have been given less attention and treatment than is required as healthcare facilities were focusing more on the recovery of patients infected with COVID-19. Moreover, in the wake of the lockdown and disruptions in supply chains, factory operations were reduced, resulting in a reduction of clinical trials and the inaccessibility of important raw materials, monoclonal antibodies (mAbs), linkers, and technology required for manufacturing ADCs. All these factors have adversely affected the growth of the global antibody-drug conjugate market during the pandemic.

Global ADC Market- By Type

The global ADC market is segmented into cleavable linkers and non-cleavable linkers based on types. The cleavable linkers segment accounted for the largest market share in 2021. Followed by cleavable linkers, non-cleavable linkers held  significant market share in the industry. Cleavable Linkers are the most prevalent linkers across the ADCs.  Due to the varying cancer variants causing distinct toxicities in cancer cells and tumors, the research and development for non-linear technologies is becoming more complex, leading to a greater share for cleavable linkers over non-cleavable linkers in the market.

  Global ADC Market Share

Global ADC Market- By End User

Based on end-users, the global ADC market is segmented into research institutes, biotechnology companies, hospitals, and clinics. The biotechnology companies segment accounted for the largest market share in 2021. ADC technology has become a powerful tool for targeting cancer therapy due to advancements across bioengineering, effective cytotoxic payload, and linker chemistry. In addition to this, in July 2021, the National Institute of Standards and Technology (NIST) of the U.S. Department of Commerce announced two grants totaling USD 153 million toward the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL). With ADCs on their aspirational roadmap, they will generate ample ADC drugs in the coming years, contributing to the segmental growth of the market.

Global ADC Market- Regional Insights

Based on regions, the global ADC market is segmented into North America, Europe, the Asia-Pacific, Latin America, and the Middle East & Africa. North America held the largest market share in 2021. On the other hand, the Asia-Pacific region is expected to hold the largest CAGR during the forecast period.  North America has been a breeding ground for ADC drug manufacturers due to the growing awareness of chemotherapy alternatives and the availability of a large market, as well as the high level of spending on R&D in biopharmaceutical firms. This makes the region a prime growth area for the market.

Global ADC Market - Competitive Landscape

The global ADC market is highly consolidated, with key players acquiring a more significant market share. As a result of this consolidation, the newer entrants find it difficult to establish themselves in the market and offer exclusive ADC products to their customers. The major companies in the global ADC market include F. Hoffmann-La Roche AG, Seagen, Inc. (Seattle Genetics Inc.), Daiichi Sankyo Company Ltd., AstraZeneca plc, Pfizer Inc., GlaxoSmithKline plc, Gilead Sciences, Inc., Takeda Pharmaceutical Company Limited, Genentech Inc., Astellas Pharma Inc., and other prominent players.

Recent Developments

August 2021: Roche announced that the pivotal phase III POLARIX trial investigating Polivy (polatuzumab vedotin) in combination with MabThera®/Rituxan® (rituximab) plus cyclophosphamide, doxorubicin and prednisone (R-CHP) versus MabThera/Rituxan plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP), achieved the primary endpoint by demonstrating a significantly enhanced progression-free survival rate for patients diagnosed with untreated diffuse large B-cell lymphoma (DLBCL). Safety outcomes in this trial were similar to previous ones.

 

Scope of the Report:

Attribute Details
Years Considered Historical data – 2018-2021
Base Year – 2021
Forecast – 2022 – 2027
Facts Covered Revenue in USD Million 
Market Coverage United States, Canada, Germany, United Kingdom, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, Saudi Arabia, United Arab Emirates, South Africa
Product/Service Segmentation By Type, By Application, By End User, By Region
Key Players The major players in the global ADC market are F. Hoffmann-La Roche AG, Seagen, Inc. (Seattle Genetics Inc.), Daiichi Sankyo Company Ltd., AstraZeneca plc, Pfizer Inc., GlaxoSmithKline plc, Gilead Sciences, Inc., Takeda Pharmaceutical Company Limited, Genentech Inc., Astellas Pharma Inc., and other prominent players.

 

By Type

  • Cleavable Linker
  • Non-cleavable Linker

By Application

  • Blood Cancer
  • Leukemia
  • Multiple Myeloma
  • Lymphoma
  • Breast Cancer
  • Urothelial Cancer & Bladder Cancer
  • Others

By End-Users

  • Research Institutes
  • Biotechnology Companies
  • Hospitals
  • Clinics

By Region

  • North America
  • Europe
  • Asia-Pacific (APAC)
  • Latin America (LATAM)
  •  Middle-East & Africa (MEA)
  1. Research Framework
    1. Research Objective
    2. Product Overview
    3. Market Segmentation
  2. Research Methodology
    1. Qualitative Research
      1. Primary and Secondary Sources
    2. Quantitative Research
      1. Primary and Secondary Sources
    3. Breakdown of Primary Research Respondents
      1. Secondary Research
      2. Primary Research
    4. Breakdown of Primary Research Respondents, By Industry Participants
    5. Key Questionnaire asked during Primary Interviews
    6. Key Primary Responses
    7. Market Size Estimation
    8. Assumption for the Study
    9. Market Breakdown & Data Triangulation
  3. Executive Summary
  4. Global Antibody Drug Conjugate Market – Industry Insights
    1. Industry Value Chain Analysis
    2. DROC Analysis
      1. Growth Drivers
      2. Restraints
      3. Opportunity
      4. Challenges
    3. Regulatory Framework
    4. Antibody Drug Conjugates Mechanism of Action
    5. Porter’s Five Forces Analysis
  5. Global Antibody Drug Conjugate Market Overview
    1. Market Estimates & Forecast by Value, 2017-2027
      1. By Value (USD Million)
    2. Market Share & Forecast
      1. By Type
        1. Cleavable Linker
        2. Non-cleavable Linker
      2. By Application
        1. Blood Cancer
          1. Leukemia
          2. Multiple Myeloma
          3. Lymphoma
        2. Breast Cancer
        3. Urothelial Cancer & Bladder Cancer
        4. Others
      3. By End Users
        1. Research Institutes
        2. Biotechnology Companies
        3. Hospitals
        4. Clinics
      4. By Region
        1. North America
        2. Europe
        3. The Asia-Pacific (APAC)
        4. Latin America (LATAM)
        5. The Middle-East & Africa (MEA)
  6. North America Antibody Drug Conjugate Market Overview
    1. Market Size and Forecast
      1. By Value (USD Million), 2017-2027
    2. Market Share and Forecast
      1. By Type
      2. By Application
      3. By End Users
      4. By Country
        1. U.S.
        2. Canada
  7. Europe Antibody Drug Conjugate Market Overview
    1. Market Size and Forecast
      1. By Value (USD Million), 2017-2027
    2. Market Share and Forecast
      1. By Type
      2. By Application
      3. By End Users
      4. By Country
        1. Germany
        2. U.K.
        3. France
        4. Italy
        5. Rest of Europe
  8. Asia Pacific Antibody Drug Conjugate Market Overview
    1. Market Size and Forecast
      1. By Value (USD Million), 2017-2027
    2. Market Share and Forecast
      1. By Type
      2. By Application
      3. By End Users
      4. By Country
        1. China
        2. India
        3. Japan
        4. South Korea
        5. Rest of Asia-Pacific
  9. Latin America Antibody Drug Conjugate Market Overview
    1. Market Size and Forecast
      1. By Value (USD Million), 2017-2027
    2. Market Share and Forecast
      1. By Type
      2. By Application
      3. By End Users
      4. By Country
        1. Argentina
        2. Brazil
        3. Rest of LATAM
  10. Middle East & Africa Antibody Drug Conjugate Market Overview
    1. Market Size and Forecast
      1. By Value (USD Million), 2017-2027
    2. Market Share and Forecast
      1. By Type
      2. By Application
      3. By End Users
      4. By Country
        1. Saudi Arabia
        2. UAE
        3. South Africa
        4. Rest of Middle East & Africa
  11. List of Antibody Drug Conjugates Patent Landscape
  12. Antibody Drug Conjugates Pipeline Analysis
  13. Competitive Landscape
      1. List of Key Producers and Their Offerings
      2. Market Share / Ranking Analysis (2020)
      3. Competitive Benchmarking, By Operating Parameters
      4. Antibody-Drug Conjugate Licensing and Merger and Acquisition (M&A) Deals
  14. Impact of COVID-19 Across Industry
  15. Company Profiles (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook) *
    1. Takeda Pharmaceutical Company Ltd.
    2. F. Hoffmann-La Roche AG
    3. Pfizer, Inc.
    4. AstraZeneca
    5. Gilead Sciences, Inc.
    6. Astellas Pharma
    7. Seagen, Inc.
    8. Daiichi Sankyo Company Ltd.
    9. GlaxoSmithKline Plc
    10. Genentech Inc.
  16. Key Strategic Recommendations

 

* Financial information in case of non-listed companies will be provided as per availability

**The segmentation and the companies are subjected to modifications based on in-depth secondary for the final deliverable

 

List of Figures

 

Fig 1: Global ADC Market Segmentation

Fig 2: Global ADC Market Size (USD Million)

Fig 3: Global ADC Market, By Type (in %), 2020

Fig 4: Global ADC Market: Industry Value Chain

Fig 5: Global ADC Market: History of ADC development

Fig 6: Global ADC Market: Mechanism of Action

Fig 7: Porters Five Forces Analysis

Fig 8: Global ADC Market Size, By Value (USD Million), 2017-2027

Fig 9: Global ADC Market Share (%), By Type, By Value, 2017-2027

Fig 10: Global ADC Market Share (%), By Application, By Value, 2017-2027

Fig 11: Estimated Number of New Cases in 2020, Worldwide

Fig 12: Global ADC Market Share (%), By Application, By Blood Cancer, By Value, 2017-2027

Fig 13: Global ADC Market Share (%), By End User, By Value, 2017-2027

Fig 14: Global ADC Market Share (%), By Region, By Value, 2017-2027

Fig 15: North America ADC Market Size, By Value (USD Million), 2017-2027

Fig 16: North America ADC Market Share (%), By Type, By Value, 2017-2027

Fig 17: North America ADC Market Share (%), By Application, By Value, 2017-2027

Fig 18: North America ADC Market Share (%), By Application, By Blood Cancer, By Value, 2017-2027

Fig 19: North America ADC Market Share (%), By End User, By Value, 2017-2027

Fig 20: North America ADC Market Share (%), By Region, By Value, 2017-2027

Fig 21: Europe ADC Market Size, By Value (USD Million), 2017-2027

Fig 22: Europe ADC Market Share (%), By Type, By Value, 2017-2027

Fig 23: Europe ADC Market Share (%), By Application, By Value, 2017-2027

Fig 24: Europe ADC Market Share (%), By Application, By Blood Cancer, By Value, 2017-2027

Fig 25: Europe ADC Market Share (%), By End User, By Value, 2017-2027

Fig 26: Europe ADC Market Share (%), By Region, By Value, 2017-2027

Fig 27: Asia-Pacific ADC Market Size, By Value (USD Million), 2017-2027

Fig 28: Asia-Pacific ADC Market Share (%), By Type, By Value, 2017-2027

Fig 29: Asia-Pacific ADC Market Share (%), By Application, By Value, 2017-2027

Fig 30: Asia-Pacific ADC Market Share (%), By Application, By Blood Cancer, By Value, 2017-2027

Fig 31: Asia-Pacific ADC Market Share (%), By End User, By Value, 2017-2027

Fig 32: Asia-Pacific ADC Market Share (%), By Region, By Value, 2017-2027

Fig 33: Latin America ADC Market Size, By Value (USD Million), 2017-2027

Fig 34: Latin America ADC Market Share (%), By Type, By Value, 2017-2027

Fig 35: Latin America ADC Market Share (%), By Application, By Value, 2017-2027

Fig 36: Latin America ADC Market Share (%), By Application, By Blood Cancer, By Value, 2017-2027

Fig 37: Latin America ADC Market Share (%), By End User, By Value, 2017-2027

Fig 38: Latin America ADC Market Share (%), By Region, By Value, 2017-2027

Fig 39: Middle East & Africa ADC Market Size, By Value (USD Million), 2017-2027

Fig 40: Middle East & Africa ADC Market Share (%), By Type, By Value, 2017-2027

Fig 41: Middle East & Africa ADC Market Share (%), By Application, By Value, 2017-2027

Fig 42: Middle East & Africa ADC Market Share (%), By Application, By Blood Cancer, By Value, 2017-2027

Fig 43: Middle East & Africa ADC Market Share (%), By End User, By Value, 2017-2027

Fig 44: Middle East & Africa ADC Market Share (%), By Region, By Value, 2017-2027

Fig 45: Global ADC Market: Leading Companies

Fig 46: Global ADC Market: Market Share Analysis, 2020

 

List of Tables

 

Table 1: Percentage of people across age intervals with risk of developing cancer, United States, 2015-2017

Table 2: Key ADC parameters that require optimization for clinical efficacy

Table 3: Global ADC Market Size (USD Million), By Type, By Value, 2017-2027

Table 4: Global ADC Market Size (USD Million), By Application, By Value, 2017-2027

Table 5: Global ADC Market Size (USD Million), By Application, By Blood Cancer, By Value, 2017-2027

Table 6: Global ADC Market Size (USD Million), By End User, By Value, 2017-2027

Table 7: Global ADC Market Size (USD Million), By Region, By Value, 2017-2027

Table 8: North America ADC Market Size (USD Million), By Type, By Value, 2017-2027

Table 9: North America ADC Market Size (USD Million), By Application, By Value, 2017-2027

Table 10: North America ADC Market Size (USD Million), By Application, By Blood Cancer, By Value, 2017-2027

Table 11: North America ADC Market Size (USD Million), By End User, By Value, 2017-2027

Table 12: North America ADC Market Size (USD Million), By Region, By Value, 2017-2027

Table 13: Europe ADC Market Size (USD Million), By Type, By Value, 2017-2027

Table 14: Europe ADC Market Size (USD Million), By Application, By Value, 2017-2027

Table 15: Europe ADC Market Size (USD Million), By Application, By Blood Cancer, By Value, 2017-2027

Table 16: Europe ADC Market Size (USD Million), By End User, By Value, 2017-2027

Table 17: Europe ADC Market Size (USD Million), By Region, By Value, 2017-2027

Table 18: Asia-Pacific ADC Market Size (USD Million), By Type, By Value, 2017-2027

Table 19: Asia-Pacific ADC Market Size (USD Million), By Application, By Value, 2017-2027

Table 20: Asia-Pacific ADC Market Size (USD Million), By Application, By Blood Cancer, By Value, 2017-2027

Table 21: Asia-Pacific ADC Market Size (USD Million), By End User, By Value, 2017-2027

Table 22: Asia-Pacific ADC Market Size (USD Million), By Region, By Value, 2017-2027

Table 23: Latin America ADC Market Size (USD Million), By Type, By Value, 2017-2027

Table 24: Latin America ADC Market Size (USD Million), By Application, By Value, 2017-2027

Table 25: Latin America ADC Market Size (USD Million), By Application, By Blood Cancer, By Value, 2017-2027

Table 26: Latin America ADC Market Size (USD Million), By End User, By Value, 2017-2027

Table 27: Latin America ADC Market Size (USD Million), By Region, By Value, 2017-2027

Table 28: Middle East & Africa ADC Market Size (USD Million), By Type, By Value, 2017-2027

Table 29: Middle East & Africa ADC Market Size (USD Million), By Application, By Value, 2017-2027

Table 30: Middle East & Africa ADC Market Size (USD Million), By Application, By Blood Cancer, By Value, 2017-2027

Table 31: Middle East & Africa ADC Market Size (USD Million), By End User, By Value, 2017-2027

Table 32: Middle East & Africa ADC Market Size (USD Million), By Region, By Value, 2017-2027

Table 33: List of Antibody Drug Conjugates Patent

Table 34: List of Antibody Drug Conjugates Approved by FDA

Table 35: List of Antibody Drug Conjugates In Clinical trials

Table 36: ADC clinical trials in Recruiting Status

Table 37: List of ADC in Phase 1 Clinical Trials

Table 38: List of ADC in Phase 2 Clinical Trials

Table 39: List of ADC in Phase 3 Clinical Trials

Table 40: List of Key Players and Their Offerings

Table 41: Competitive Benchmarking, by Operating Parameters

Table 42: Antibody-Drug Conjugate Licensing and Merger and Acquisition (M&A) Deals.

Table 43: Takeda Pharmaceutical Company Limited Business Overview

Table 44: Takeda Pharmaceutical Company Limited Financial Analysis (USD Million)

Table 45: F. Hoffmann-La Roche AG Business Overview

Table 46: F. Hoffmann-La Roche AG Financial Analysis (USD Million)

Table 47: Pfizer Inc. Company Overview

Table 48: Pfizer Inc. Financial Analysis (USD Millions)

Table 49: AstraZeneca plc Company Overview

Table 50: AstraZeneca plc Financial Analysis (USD Millions)

Table 51: GiLead Sciences Inc. Business Overview

Table 52: GiLead Sciences Inc. Financial Analysis (USD Million)

Table 53: Astellas Pharma Inc. Business Overview

Table 54: Astellas Pharma Inc. Financial Analysis

Table 55: Seagen Inc.  Business Overview

Table 56: Seagen Inc. Financial Analysis (USD Million)

Table 57: Daiichi Sankyo Company Ltd.  Business Overview

Table 58: Daiichi Sankyo Company Ltd. Financial Analysis (USD Million)

Table 59: GlaxoSmithKline Plc. Limited Business Overview

Table 60: GlaxoSmithKline Plc. Financial Analysis (USD Million)

Table 61: Genentech, Inc. Business Overview

Table 62: F. Hoffmann-La Roche AG Financial Analysis (USD Million)

Market Segmentation

By Type

  • Cleavable Linker
  • Non-cleavable Linker

By Application

  • Blood Cancer
  • Leukemia
  • Multiple Myeloma
  • Lymphoma
  • Breast Cancer
  • Urothelial Cancer & Bladder Cancer
  • Others

By End-Users

  • Research Institutes
  • Biotechnology Companies
  • Hospitals
  • Clinics

By Region

  • North America
  • Europe
  • Asia-Pacific (APAC)
  • Latin America (LATAM)
  •  Middle-East & Africa (MEA)
No data available

To request a free sample copy of this report, please complete the form below.

We value your investment and offer free customization with every report to fulfil your exact research needs.

This website is secure and your personal details are safe.

Frequently Asked Questions (FAQs):

Ans: The global ADC market reached USD 4,053.7 million in 2021 across the globe.
Ans: The growing advancement in linker technology, coupled with extensive research & development in the medical field, has driven the growth of the global ADC market.
Ans: The major companies in the global ADC market include F. Hoffmann-La Roche AG, Seagen, Inc. (Seattle Genetics Inc.), Daiichi Sankyo Company Ltd., AstraZeneca plc, Pfizer Inc., GlaxoSmithKline plc, Gilead Sciences, Inc., Takeda Pharmaceutical Company Limited, Genentech Inc., Astellas Pharma Inc., and other prominent players.
Ans: Based on end-users, the biotechnology companies accounted for the largest share in the global ADC market.
Ans: The Asia-Pacific region is anticipated to have the highest CAGR during the forecast period.